Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension
- 1 November 2001
- journal article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 88 (9), 1060-1063
- https://doi.org/10.1016/s0002-9149(01)01995-6
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseAnnals of Internal Medicine, 2000
- Nongeometric quantitative assessment of right and left ventricular function: Myocardial performance index in normal children and patients with Ebstein anomalyJournal of the American Society of Echocardiography, 1998
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionThe New England Journal of Medicine, 1998
- Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary HypertensionCirculation, 1997
- Doppler echocardiographic index for assessment of global right ventricular functionJournal of the American Society of Echocardiography, 1996
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionThe New England Journal of Medicine, 1996
- Pharmacodynamic profile of prostacyclinThe American Journal of Cardiology, 1995
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991
- Primary Pulmonary HypertensionAnnals of Internal Medicine, 1987
- Primary pulmonary hypertension: natural history and the importance of thrombosis.Circulation, 1984